



FEBRUARY 2015 VOLUME 3 NUMBER 2

College of Cardiology

INSIDE THIS ISSUE

MINI-FOCUS ISSUE: DECOMPENSATED HEART FAILURE

Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure

Robert J. Mentz, Susanna R. Stevens, Adam D. DeVore, Anuradha Lala, Justin M. Vader, Omar F. AbouEzzeddine, Prateeti Khazanie, Margaret M. Redfield, Lynne W. Stevenson, Christopher M. O'Connor, Steven R. Goldsmith, Bradley A. Bart, Kevin J. Anstrom, Adrian F. Hernandez, Eugene Braunwald, G. Michael Felker

High-dose diuretics in acute heart failure (AHF) patients are thought to activate the renin-angiotensinaldosterone system (RAAS); and alternative decongestion strategies, such as ultrafiltration, have been proposed to mitigate this activation. This study analyzed 427 AHF patients enrolled in the DOSE-AHF (Diuretic Optimization Strategies in Acute Heart Failure) and CARRESS-HF (Cardiorenal Rescue Study in Acute Decompensated Heart Failure) studies. We assessed the relationships between 2 markers of renin-angiotensin-aldosterone system (RAAS) activation (plasma renin activity [PRA] and aldosterone) from baseline to 72 h to 96 h with decongestion strategy and 60-day outcomes. High-dose loop diuretic therapy did not result in RAAS activation greater than that with low-dose therapy. Ultrafiltration resulted in PRA increase greater than that of stepped pharmacologic care. Neither PRA nor aldosterone was significantly associated with outcomes.

SEE ADDITIONAL CONTENT ONLINE

EDITORIAL COMMENT

Renin-Angiotensin-Aldosterone System Activation During Decongestion in Acute Heart Failure: Friend or Foe? Frederik H. Verbrugge, W.H. Wilson Tang, Wilfried Mullens

97

108

112

Advance Directives Among Hospitalized Patients With Heart Failure Javed Butler, Zachary Binney, Andreas Kalogeropoulos, Melissa Owen, Carolyn Clevenger, Debbie Gunter, Vasiliki Georgiopoulou, Tammie Quest

Discussing advance directives (ADs) with patients with heart failure (HF) is critical for identifying treatment goals consistent with patients' values and preferences. This study assessed the frequency and correlates of ADs among 44,768 admissions for HF from 24,291 patients over 5 years. Only 12.7% of patients had documented ADs. Age, sex, race, socioeconomic status, risk for adverse in-hospital outcomes, length of stay, hospice discharge, palliative care consultation, and a do-not-resuscitate order were associated with having ADs. An increase in ADs over time was noted, but >80% of patients did not have ADs documented at the end of the study period.

SEE ADDITIONAL CONTENT ONLINE

EDITORIAL COMMENT Advanced Care Planning: Care to Plan in Advance Lynne Warner Stevenson, Arden O'Donnell

122





JACC Heart Failure

PAGE A-14

FEBRUARY 2015 VOLUME 3, NUMBER 2

Intravenous Fluids in Acute Decompensated Heart Failure

Behnood Bikdeli, Kelly M. Strait, Kumar Dharmarajan, Shu-Xia Li, Purav Mody, Chohreh Partovian, Steven G. Coca, Nancy Kim, Leora I. Horwitz, Jeffrey M. Testani, Harlan M. Krumholz

Intravenous fluids are provided to many hospitalized patients. This study examined 131,430 hospitalizations in patients with heart failure and determined the use of intravenous fluids among patients receiving loop diuretics during the first 2 days of hospitalization, as well as in-hospital outcomes. Overall, patients in 13,806 (11%) of the hospitalizations were treated with intravenous fluids and had higher rates of subsequent critical care admission, intubation, dialysis, and hospitalized patients with heart failure and diuretic therapy also receive intravenous fluids during their early inpatient care. Such practice is associated with worse outcomes and warrants further investigation.

SEE ADDITIONAL CONTENT ONLINE

EDITORIAL COMMENT

Simultaneous Use of Intravenous Fluids and Diuretics in Patients Hospitalized With Heart Failure: When the Left Hand Does Not Know What the Right Hand Is Doing Larry A. Allen

STATE-OF-THE-ART PAPER

Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure

Alessandra Dei Cas, Sadiya S. Khan, Javed Butler, Robert J. Mentz, Robert O. Bonow, Angelo Avogaro, Diethelm Tschoepe, Wolfram Doehner, Stephen J. Greene, Michele Senni, Mihai Gheorghiade, Gregg C. Fonarow

The prevalence of patients with concomitant heart failure (HF) and diabetes mellitus (DM) continues to increase with the general aging of the population. In patients with chronic HF, prevalence of DM is 24% compared with 40% in those hospitalized with worsening HF. Patients with concomitant HF and DM have diverse pathophysiologic, metabolic, and neurohormonal abnormalities that potentially contribute to worse outcomes than those without comorbid DM. In addition, although stable HF outpatients with DM show responses that are similar to those of patients without DM undergoing evidence-based therapies, it is unclear whether hospitalized HF patients with DM will respond similarly to novel investigational therapies. These data support the need to re-evaluate the epidemiology, pathophysiology, and therapy of HF patients with concomitant DM. This paper discusses the role of DM in HF patients and underscores the potential need for the development of targeted therapies.

127

134

136

Download English Version:

https://daneshyari.com/en/article/2942478

Download Persian Version:

https://daneshyari.com/article/2942478

Daneshyari.com